KALY Phase One Cannabis Extract COPD Research To Be Published This Friday March 22 2019
March 20 2019 - 1:17PM
InvestorsHub NewsWire
KALY Phase One Cannabis Extract
COPD Research To Be Published This Friday March 22 2019
Dallas, TX -- March 20, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced the company plans to publish its
phase one research on the pilot treatment
of Chronic Obstructive Pulmonary Disease (COPD) in
primates. The research paper comes from Professor Jeffry
Osbourn, Ph.D., from the University of Kentucky and the principal
of Biomedical Science Research Group (BSRG). Professor
Osbourn and KALY CEO Frederick Ferri met last week to coordinate a
phase two study of the pilot treatment. The primate study adds to the Kali-Extracts in vitro
genomics study, previously announced, to evaluate the impact of its
pharmaceutical grade cannabis extracts in combination with other
therapies on COPD patients. The World Health Organization
estimates 65 million people worldwide are afflicted with moderate
to severe COPD and GlobalData forecasts that the COPD treatment
market will reach $14.1 billion by
2025.
KALY is a health and wellness company set to
generate revenue from its patented cannabis extraction technology
through overlapping go-to-market strategies. In addition
developing pharmaceutical products internally and through
partnerships, KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. The company has made recent advances
in partnership with Puration, Inc. (USOTC: PURA) (“PURA”)
developing a CBD extract for infusion into a beverage at a 25 mg
concentration. The first target beverage for the 25 mg CBD
concentrate beverage is a private labeled health water for Generex
Biotechnology (OTCBB: GNBT).
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024